Abstract
Background: Bursal Pentapeptide (BPP)-(III-V) are peptides isolated from the Bursa of Fabricius (BF).
Method: The peptides' adjuvant activities were evaluated in mice immunized with the H9N2 avian influenza vaccine.
Results: The results showed that BPP-IV did not promote humoral or cellular immune responses. BPP-III had no effect on antibody production, but increased populations of CD3+ and CD8+ T cells, CTL levels and proliferation activities of splenic T-lymphocytes. BPP-V increased the level of antibodies (HI, IgG and its subtype IgG1) and the cytokine IL-4, as well as the ratio of CD3+ T cells and its subsets CD4+ and CD8+ T cells, BPP-V also increased CTL level and promoted the proliferation activity of T- and B-lymphocyte. Furthermore, in animal challenge experiment, BPP-III and BPP-V reduced viral RNA copies and viral titers, and reduced inflammatory cell infiltration.
Conclusion: In summary, BPP-IV did not have an effect on specific immune responses, therefore it could not reduce pathological damage in mice lungs; BPP-III provided resistance to the antigen through the cell-mediated immune response; BPP-V enhanced both humoral and cellular immune responses, therefore provided protections against the H9N2 Avian Influenza Virus (AIV). Altogether, BPP-III and BPP-V could be adjuvant candidates for the H9N2 avian influenza vaccine.
Keywords: Bursal pentapeptided-(III-V), adjuvants, humoral immune response, cellular immune response, immunoprotection test, avian influenza virus.
Graphical Abstract
Protein & Peptide Letters
Title:Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine
Volume: 25 Issue: 8
Author(s): Jiangfei Zhou, Cong Zhang, Zhixin Liu, Yongqing Liu, Kairui Cai, Tengfei Shen, Chengshui Liao*Chen Wang*
Affiliation:
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, Henan,China
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, Henan,China
Keywords: Bursal pentapeptided-(III-V), adjuvants, humoral immune response, cellular immune response, immunoprotection test, avian influenza virus.
Abstract: Background: Bursal Pentapeptide (BPP)-(III-V) are peptides isolated from the Bursa of Fabricius (BF).
Method: The peptides' adjuvant activities were evaluated in mice immunized with the H9N2 avian influenza vaccine.
Results: The results showed that BPP-IV did not promote humoral or cellular immune responses. BPP-III had no effect on antibody production, but increased populations of CD3+ and CD8+ T cells, CTL levels and proliferation activities of splenic T-lymphocytes. BPP-V increased the level of antibodies (HI, IgG and its subtype IgG1) and the cytokine IL-4, as well as the ratio of CD3+ T cells and its subsets CD4+ and CD8+ T cells, BPP-V also increased CTL level and promoted the proliferation activity of T- and B-lymphocyte. Furthermore, in animal challenge experiment, BPP-III and BPP-V reduced viral RNA copies and viral titers, and reduced inflammatory cell infiltration.
Conclusion: In summary, BPP-IV did not have an effect on specific immune responses, therefore it could not reduce pathological damage in mice lungs; BPP-III provided resistance to the antigen through the cell-mediated immune response; BPP-V enhanced both humoral and cellular immune responses, therefore provided protections against the H9N2 Avian Influenza Virus (AIV). Altogether, BPP-III and BPP-V could be adjuvant candidates for the H9N2 avian influenza vaccine.
Export Options
About this article
Cite this article as:
Zhou Jiangfei , Zhang Cong , Liu Zhixin , Liu Yongqing, Cai Kairui , Shen Tengfei , Liao Chengshui *, Wang Chen*, Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine, Protein & Peptide Letters 2018; 25 (8) . https://dx.doi.org/10.2174/0929866525666180806110928
DOI https://dx.doi.org/10.2174/0929866525666180806110928 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocapsulated Ascorbic Acid in Combating Cerebral Ischemia Reperfusion- Induced Oxidative Injury in Rat Brain
Current Alzheimer Research Structure- and Fragment-Based Approaches to Protease Inhibition
Current Topics in Medicinal Chemistry Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry A Historical Overview of the Heterologous Expression of Mammalian UDP-Glucuronosyltransferase Isoforms Over the Past Twenty Years
Current Drug Metabolism Synthesis of LDH Nanosheets and their Layer-by-Layer Assembly
Recent Patents on Nanotechnology Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats
Current Molecular Pharmacology Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Reactive Astrogliosis: Role in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Antithyroid Drugs Inactivate TSH Binding to the TSH Receptor by their Reducing Action
Endocrine, Metabolic & Immune Disorders - Drug Targets Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Pathogenesis of SLE Dermatitis - A Reflection of the Process in SLE Nephritis?
Current Rheumatology Reviews Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry Current Progress in the Development of HIV Vaccines
Current Pharmaceutical Design Potential Therapeutic Application of the Association of Vitamins C and K3 in Cancer Treatment
Current Medicinal Chemistry